Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520401 | 0.82 | CYP3A4 (0.36) | ADRB2ADRB1CYP3A4ALDH1A1TSHR | |
| SCHEMBL2434618 | 0.82 | CYP3A4 (0.56) | ADRB2ADRB1CYP3A4ALDH1A1TSHR | |
| SCHEMBL10215752 | 0.80 | ADRB2 (0.41) | ADRB2ADRB1CYP3A4TSHRGLA | |
| SCHEMBL11694963 | 0.80 | ADRB2 (0.43) | ADRB2ADRB1CYP3A4ALDH1A1POLB | |
| SCHEMBL29778819 | 0.80 | ADRB2 (0.43) | ADRB2ADRB1CYP3A4ALDH1A1TSHR | |
| SCHEMBL21603537 | 0.80 | ADRB2 (0.43) | ADRB2ADRB1CYP3A4ALDH1A1TSHR | |
| SCHEMBL14300440 | 0.78 | ADRB2 (0.42) | ADRB2ADRB1CYP3A4ALDH1A1TSHR | |
| SCHEMBL18007552 | 0.78 | ALDH1A1 (0.37) | ADRB2ADRB1CYP3A4ALDH1A1TSHR | |
| SCHEMBL12069198 | 0.78 | GLA (0.33) | ADRB2ADRB1CYP3A4TSHRGLA | |
| SCHEMBL1000064 | 0.78 | ADRB2 (0.42) | ADRB2ADRB1CYP3A4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| EP-0912492-B1 | METHOD FOR PREPARING HALOGENATED 2-AMINO OR 2-ACETAMIDO TRIFLUOROMETHYLBENZENE DERIVATIVES | RHODIA CHIMIE SA (FR) | 2002-09-25 | — | — | EP | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| US-9409917-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-09 | — | — | US | disclosed |
| EP-2734526-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-9221832-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-29 | — | — | US | disclosed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | disclosed |
| EP-1282606-B1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-22 | — | — | EP | disclosed |
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2804865-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-11-26 | — | — | EP | disclosed |
| WO-1998002409-A1 | METHOD FOR PREPARING HALOGENATED 2-AMINO OR 2-ACETAMIDO TRIFLUOROMETHYLBENZENE DERIVATIVES | RHODIA CHIMIE (FR) | 1998-01-22 | — | — | WO | disclosed |
| EP-0280156-B1 | PROCESS FOR THE PREPARATION OF ACETOACETYLARYLAMIDES-HETEROARYLAMIDES RESPECTIVELY OF DEACTIVED AROMATIC COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0280156-A2 | Process for the preparation of acetoacetylarylamides-heteroarylamides respectively of deactived aromatic compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-31 | — | — | EP | disclosed |
| EP-0043795-B1 | MONOAZO COMPOUNDS | CIBA-GEIGY AG (CH) | 1984-08-01 | — | — | EP | disclosed |
| US-4448719-A | TEXTILES; COLORFAST | CIBA-GEIGY CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
| EP-0043795-A2 | Monoazo compounds | CIBA-GEIGY AG (CH) | 1982-01-13 | — | — | EP | disclosed |
| US-4008278-A | FROM AN AMINO-BENZOTRIFLUORIDE AND A HALOGEN SOURCE | OLIN CORPORATION (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | ADRB2 282/4885ADRB1 173/4885CYP3A4 174/4885 |
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX3 | ADRB2 157/4885ADRB1 102/4885CYP3A4 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.